{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ziftomenib", "query": { "intervention": "ziftomenib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ziftomenib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T03:20:37.631Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06448013", "title": "A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Gemtuzumab", "type": "DRUG" }, { "name": "Ziftomenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 22, "start_date": "2025-03-07", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-06T03:20:37.631Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06448013" }, { "nct_id": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Mixed Lineage Leukemia Gene Mutation", "Refractory AML", "AML With Mutated NPM1", "Acute Myeloid Leukemia Recurrent", "Acute Myeloid Leukemia, in Relapse", "NPM1 Mutation", "KMT2Ar", "Myeloid Sarcoma", "Nucleophosmin 1-mutated Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2023-07-18", "completion_date": "2030-04", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-09-06T03:20:37.631Z", "location_count": 44, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05735184" }, { "nct_id": "NCT06001788", "title": "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML", "AML With Mutated NPM1", "Hematologic Malignancy", "KMT2Ar", "NPM1 Mutation", "MLL Rearrangement", "Leukemia", "Acute Myeloid Leukemia", "Leukemia, Myeloid", "Leukemia, Myeloid, Acute", "Acute Leukemia", "Neoplasms by Histologic Type" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Granulocyte colony-stimulating factor", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2024-02-22", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-06T03:20:37.631Z", "location_count": 38, "location_summary": "Gilbert, Arizona • Los Angeles, California • Orange, California + 32 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06001788" }, { "nct_id": "NCT07355335", "title": "Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "KMT2A-rearranged", "NPM1-mutant Refractory or Relapsed AML" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 24, "start_date": "2026-07-09", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-09-06T03:20:37.631Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07355335" }, { "nct_id": "NCT06655246", "title": "A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Tumor (GIST)", "Gastrointestinal Stromal Cancer", "Gastrointestinal Stromal Neoplasm", "Gastrointestinal Stromal Tumor, Malignant", "Gastrointestinal Stromal Cell Tumors" ], "interventions": [ { "name": "ziftomenib", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2025-03-27", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-06T03:20:37.631Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06655246" }, { "nct_id": "NCT06930352", "title": "Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ziftomenib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Uma Borate", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2026-10-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-06T03:20:37.631Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06930352" }, { "nct_id": "NCT07007312", "title": "Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine (AZA)", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine (Ara-C)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1300, "start_date": "2025-09-26", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-06T03:20:37.631Z", "location_count": 42, "location_summary": "Gilbert, Arizona • Clovis, California • La Jolla, California + 35 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Clovis", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07007312" }, { "nct_id": "NCT04067336", "title": "First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Neoplasm", "Acute Myeloid Leukemia", "Mixed Lineage Leukemia", "Mixed Lineage Acute Leukemia", "Acute Leukemia of Ambiguous Lineage", "Mixed Phenotype Acute Leukemia", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 263, "start_date": "2019-09-12", "completion_date": "2028-10-16", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-09-06T03:20:37.631Z", "location_count": 20, "location_summary": "Gilbert, Arizona • Los Angeles, California • Jacksonville, Florida + 16 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04067336" }, { "nct_id": "NCT05848687", "title": "TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoblastic Leukemia" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "PEG asparaginase", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Ziftomenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanja Andrea Gruber", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "1 Year", "sex": "ALL", "summary": "Up to 1 Year" }, "enrollment_count": 90, "start_date": "2023-11-03", "completion_date": "2033-12", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-06T03:20:37.631Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05848687" }, { "nct_id": "NCT06769490", "title": "Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2025-07-10", "completion_date": "2030-09-15", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-09-06T03:20:37.631Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06769490" } ] }